CVE-2019-10067

Description

An issue was discovered in Open Ticket Request System (OTRS) 7.x through 7.0.6 and Community Edition 5.0.x through 5.0.35 and 6.0.x through 6.0.17. An attacker who is logged into OTRS as an agent user with appropriate permissions may manipulate the URL to cause execution of JavaScript in the context of OTRS.

Category

5.4
CVSS
Severity: Medium
CVSS 3.1 •
CVSS 2.0 •
EPSS 0.55%
Vendor Advisory opensuse.org Vendor Advisory opensuse.org Vendor Advisory opensuse.org Vendor Advisory otrs.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
https://community.otrs.com/security-advisory-2019-05-security-update-for-otrs-framework/ patch vendor advisory
http://lists.opensuse.org/opensuse-security-announce/2020-04/msg00038.html vendor advisory broken link
http://lists.opensuse.org/opensuse-security-announce/2020-09/msg00066.html vendor advisory broken link
http://lists.opensuse.org/opensuse-security-announce/2020-09/msg00077.html vendor advisory broken link

Frequently Asked Questions

What is the severity of CVE-2019-10067?
CVE-2019-10067 has been scored as a medium severity vulnerability.
How to fix CVE-2019-10067?
To fix CVE-2019-10067, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2019-10067 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2019-10067 is being actively exploited. According to its EPSS score, there is a ~1% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.